Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Apr 22, 2026

Ducommun (DCO): Q1 2026 Earnings Preview Amid Record Backlog and Defense Strength

Key Takeaways

  • Analysts forecast Q1 2026 revenue of approximately $200 million, up roughly 3% from $194.1 million in Q1 2025.
  • Consensus EPS estimate stands at $0.72 to $0.82 per share, reflecting cautious growth amid seasonal trends, though Ducommun has consistently beaten estimates.
  • Record remaining performance obligations (RPO) of $1.106 billion at year-end 2025 provides strong revenue visibility, driven by military and space demand.
  • Gross margins expected to remain robust around 27%, building on Q4 2025's 27.7% record.
  • Investors watching for updates on defense ramps and commercial aerospace recovery signals.
  • Historical post-earnings stock moves average positive on beats, with recent quarters showing gains of 5-10%.

Earnings Context and Why It Matters

Ducommun (DCO), a key supplier of components and assemblies for aerospace, defense, and industrial sectors, is approaching its Q1 2026 earnings with solid momentum from a record-breaking 2025. Full-year revenue came in at $824.7 million, up 4.9%, even after a $107.3 million litigation charge affected net income. Adjusted EBITDA hit a record $135.6 million, or 16.4% of revenue, which underscores their strong margin discipline. In my view, this report is particularly important as it will offer visibility into defense production ramps aligned with U.S. Department of Defense priorities and any initial signs of relief from commercial aerospace destocking. With shares up notably year-to-date on backlog strength, investors are eager for confirmation of ongoing growth in this volatile sector.

Earnings Expectations

Wall Street's average call from five analysts points to Q1 2026 revenue of $199.8 million, marking modest growth both sequentially from Q4 2025's $215.8 million and year-over-year from Q1 2025's $194.1 million. The EPS consensus ranges from $0.72 (Zacks) to $0.82 (MarketBeat), a slight dip from Q1 2025's adjusted $0.83 but in line with typical seasonal patterns for the sector.

Ducommun has a strong track record, beating EPS estimates over the last eight quarters with average surprises of 15-20%—Q4 2025 saw $1.05 actual versus $0.91 expected, for instance. Key areas to monitor include RPO conversion, gross margins (27.7% in Q4), and adjusted EBITDA margins. Management didn't provide formal Q1 guidance after Q4, but they emphasized strength in missile programs through long-term agreements (LTAs) with RTX and Lockheed Martin, helping offset commercial challenges. I also checked DCO against industry peers using Tickeron’s AI Screener to gauge its relative positioning.

AI Screener

One tool I rely on regularly for digging deeper into stocks like DCO is Tickeron’s AI Screener. This AI-powered stock and ETF discovery platform lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—think industry filters, market cap, indicators, price patterns, and performance metrics. It surfaces trade ideas, breakout candidates, and market opportunities far more efficiently than manual scans, streamlining my research process. If you're screening for similar setups in aerospace and defense, it's a solid addition to your toolkit.

Market Reaction and Investor Sentiment

As we head into Q1 earnings expected on May 5, 2026, sentiment toward DCO remains cautiously optimistic, supported by the $1.1 billion RPO and favorable defense trends. The stock has responded well to prior beats, including gains after Q4 2025 despite a minor revenue shortfall. Potential risks involve commercial aerospace delays and tariff impacts, though management views them as immaterial. Implied volatility indicates a possible 10-12% move post-earnings, which is standard for the sector.

Forward Outlook and Key Factors to Monitor

Post-Q1, the focus will shift to any full-year 2026 guidance, leveraging 2025's strong results. Management anticipates ramps in missile production and defense spending to boost military/space revenue, backed by LTAs and DoD priorities.

Progress in commercial aerospace will depend on Boeing's production increases and destocking normalization, which could pick up in H2 2026. One thing I'll be tracking closely is RPO evolution from $1.106 billion, book-to-bill ratios (1.3x in Q4), and margin progress toward the VISION 2027 goal of 18% adjusted EBITDA.

Additional drivers include growth in engineered products (23% of 2025 revenue, up from 15% in 2022) and tariff strategies like exemptions or pass-throughs. Broader tailwinds from steady defense budgets persist, while supply chain steadiness will affect efficiency. From what I see, these elements position DCO well for continued execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: DCO

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


DCO's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for DCO moved out of overbought territory on August 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCO as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DCO turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DCO broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DCO advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 324 cases where DCO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DCO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.191) is normal, around the industry mean (7.037). P/E Ratio (34.664) is within average values for comparable stocks, (60.208). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.077). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (3.353) is also within normal values, averaging (20.174).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 40.4B. The market cap for tickers in the group ranges from 4.49 to 1.81T. SPCX holds the highest valuation in this group at 1.81T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -8%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was -3%. NPK experienced the highest price growth at 7%, while DFSC experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 68
Price Growth Rating: 55
SMR Rating: 78
Profit Risk Rating: 73
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
DCO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of aircraft components and equipment

Industry AerospaceDefense

Profile
Details
Industry
Aerospace And Defense
Address
200 Sandpointe Avenue
Phone
+1 657 335-3665
Employees
2265
Web
https://www.ducommun.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.